Interactions of the anti-FcRn monoclonal antibody, rozanolixizumab, with Fcγ receptors and functional impact on immune cells in vitro

Interactions of the anti-FcRn monoclonal antibody, rozanolixizumab, with Fcγ receptors and functional impact on immune cells in vitro

Rozanolixizumab is a humanized anti-neonatal Fc receptor (FcRn) monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4) sub-class, currently in clinical development for the treatment of IgG autoantibody-driven diseases. This format is frequently used for therapeutic mAbs due to its intrinsic lower...

Full description

Bibliographic Details
Main Authors: Omar S. Qureshi, Emma J. Sutton, Rosemary F. Bithell, Shauna M. West, Rona M. Cutler, Gillian McCluskey, Graham Craggs, Asher Maroof, Nicholas M. Barnes, David P. Humphreys, Stephen Rapecki, Bryan J. Smith, Anthony Shock
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:mAbs
Subjects:
FcRn
neonatal Fc receptor
rozanolixizumab
Fcγ receptor
antibody bipolar bridging
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2023.2300155

Internet

https://www.tandfonline.com/doi/10.1080/19420862.2023.2300155

Similar Items